New prostate cancer treatment aims to control disease while protecting sexual function
NCT ID NCT04025372
Summary
This study is testing if a new hormone drug called darolutamide, when given with radiation therapy, works as well as standard hormone therapy for men with intermediate-risk prostate cancer. A key goal is to see if this new combination can control the cancer while causing fewer side effects on sexual function. The trial will measure cancer control and quality of life, including erectile function, in about 234 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Associated Medical Professionals of NY
Syracuse, New York, 13210, United States
-
Beth Israel Deaconness Medical Center
Boston, Massachusetts, 02115, United States
-
Brigham and Women Hospital
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center
Milford, Massachusetts, 01757, United States
-
Dana-Farber/Brigham and Women's Cancer Center in Clinical Affiliation with South Shore Hospital
South Weymouth, Massachusetts, 02190, United States
-
NYU Langone Health
New York, New York, 10016, United States
-
NYU Long Island
Garden City, New York, 11530, United States
-
Stamford Hospital
Stamford, Connecticut, 06904, United States
-
Washington University School of Medicine in St. Louis
St Louis, Missouri, 63108, United States
-
XCancer Omaha / Urology Cancer Center
Omaha, Nebraska, 68130, United States
Conditions
Explore the condition pages connected to this study.